Stockscreener 앱 받기
81.37
1.12%
-0.4936
전일 마감가:
$81.86
열려 있는:
$82.46
하루 거래량:
2.82M
Relative Volume:
0.73
시가총액:
$47.21B
수익:
$5.88B
순이익/손실:
$1.34B
주가수익비율:
34.64
EPS:
2.3489
순현금흐름:
$799.60M
1주 성능:
-4.14%
1개월 성능:
-6.90%
6개월 성능:
+0.59%
1년 성능:
+13.80%
1일 변동 폭
$80.44
$82.53
1주일 범위
$80.80
$85.00
52주 변동 폭
$65.94
$87.89
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
EW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
81.36 | 47.50B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
105.93 | 184.41B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
92.31 | 139.09B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.80 | 136.84B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.84 | 129.21B | 34.76B | 4.79B | 5.21B | 3.7017 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-12-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-10-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-10-07 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-04-24 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Stifel | Hold → Buy |
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
J. Safra Sarasin Holding AG Buys New Shares in Edwards Lifesciences Corporation $EW - MarketBeat
Bank of New York Mellon Corp Increases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
ACQUISITIONS & MERGERS—D.D.C.: Opinion granting FTC win in Edwards Lifesciences case details reasoning - VitalLaw.com
Judge: Edwards/Jenavalve would create “total monopoly” - Global Competition Review
Sector Gamma AS Acquires 30,980 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 25,276 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Profit Review: Will Edwards Lifesciences Corporation outperform its industry peersMarket Rally & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Heart Valve Deal Was Blocked Over Innovation Concerns - Law360
Edwards Lifesciences (NYSE:EW) Issues FY 2026 Earnings Guidance - MarketBeat
What to expect from Edwards Lifesciences' Q4 2025 earnings report - MSN
Universal Beteiligungs und Servicegesellschaft mbH Raises Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Allstate Corp Buys Shares of 21,090 Edwards Lifesciences Corporation $EW - MarketBeat
VIX Spike: Can GBFH sustain earnings growthJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Action: Is Edwards Lifesciences Corporation showing insider buyingQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Edwards Lifesciences (EW) Receives New Analyst Target Price from Piper Sandler | EW Stock News - GuruFocus
Stifel raises Edwards Lifesciences stock price target to $110 on TAVR growth - Investing.com Canada
Edwards Lifesciences Corp. Still Trying To Regain Footing - AOL.com
Does Edwards Lifesciences (EW) Have Strong Double-Digit Earnings Potential? - Yahoo Finance
What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing? - Yahoo Finance
Edwards Lifesciences (NYSE:EW) S&P 500 Index Medical Device Presence - Kalkine Media
Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Short Interest Update - MarketBeat
Edwards’ Heart Valve Clips Targeted by Cardiovalve Patent Suit - Bloomberg Law News
Market Review: Whats the outlook for Edwards Lifesciences Corporations sectorPortfolio Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy - Benzinga
Edwards Lifesciences (EW) Valuation Check As Recent Share Momentum Meets Premium P/E Pricing - Yahoo Finance
Risk Report: Does Edwards Lifesciences Corporation align with a passive investing strategy2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
JPM26: Edwards Lifesciences targets 10% growth in 2026 - Yahoo Finance
Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now? - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What to Expect From Edwards Lifesciences' Q4 2025 Earnings Report - Yahoo Finance
Nordea Investment Management AB Sells 110,464 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Spire Wealth Management Decreases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
UBS Revises Edwards Lifesciences (EW) Price Target and Maintains Neutral Rating | EW Stock News - GuruFocus
Barclays Raises Price Target for Edwards Lifesciences (EW) to $1 - GuruFocus
FTC Blocks Edwards Lifesciences’ $945M JenaValve Acquisition - ocbj.com
Edwards scraps Jenavalve buy in face of FTC objections - BioWorld MedTech
Edwards Lifesciences (EW) Faces Legal Setback in Acquisition Pla - GuruFocus
Edwards Lifesciences Corp Acquisition Blocked by FTC - TradingView — Track All Markets
Hardman Johnston Global Advisors LLC Cuts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Drops Bid to Acquire JenaValve Technology - marketscreener.com
Oregon Public Employees Retirement Fund Increases Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards won’t acquire JenaValve after FTC blocks deal - MassDevice
Parnassus Investments LLC Takes $36.93 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Explores Personalized Blood Pressure Targets in New Study - MSN
US FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve - Reuters
FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve - Bitget
Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $87,328.30 in Stock - MarketBeat
Edwards Lifesciences (EW) Updates Earnings Guidance for 2023 - GuruFocus
Edwards Lifesciences (EW) Acquisition Blocked by Court - GuruFocus
Edwards says co will not acquire Jenavalve - marketscreener.com
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
자본화:
|
볼륨(24시간):